For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

In addition to improving heart failure symptoms, finerenone reduced the onset of new type 2 diabetes in patients with mildly ...

For patients with heart failure with preserved ejection fraction (HFpEF), endovascular treatment (EVT) improves left ...

Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed.

Finerenone reduced the composite of total first and recurrent heart failure (HF ... in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical ...

This marks the regulator's second backing for a use of Wegovy beyond weight loss and further strengthens Novo's case that the ...

Phase 2 Clinical Trial in Patients with Heart Failure with Preserved Ejection Fraction Expected to Begin in Q4 2024SOUTH SAN ...

The trial results indicated minimal adverse events and no evidence of immune-mediated clearance following TX45 treatment.

Quotient Sciences, Vasa Therapeutics dose first human subjects with VS-041, a novel therapy for heart failure with preserved ejection fraction: Nottingham, UK Monday, September 16 ...

The medication, finerenone, could be an effective therapy in people with heart failure who have mildly reduced or preserved ejection fraction, suggests the study, published Sunday in the New Engla ...

Finerenone reduced heart failure (HF) events and cardiovascular death in patients with HF and mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF), according to late-breaking research ...